國際新聞精選周四（2017年1月5日）

2017年1月5日 | Filed under: | Posted by: 編輯 D

Pharma stocks battered in 2016 storm

If 2015 was turbulent for the biopharma industry then 2016 was even more volatile, with the Nasdaq Biotechnology index ending the year in the red for the first time since 2008. With macroeconomic issues and pricing pressure set to continue, as well as uncertainty over President-elect Donald Trump’s policies, things could get worse before they get better.【閱讀全文】

Political ructions, poor deal-making and scandal – a bad year for big-cap medtechs

The year just passed saw more large-cap medical device companies fall further than any period since EP Vantage has been tracking their share price performance. The fallers are usually down by single-digit percentages, and there are rarely five. 2016 brings a full complement and the worst performer, Coloplast, is down an unprecedented 18%.【閱讀全文】

Tarveda Therapeutics Announces Phase 1/2a Clinical Trial of PEN-221 Underway in Patients with Neuroendocrine Tumors and Small Cell Lung Cancer

Tarveda Therapeutics, Inc., a biopharmaceutical company discovering and developing Pentarins? as a new class of potent and selective anti-cancer medicines, today announced that a Phase 1/2a clinical trial evaluating PEN-221 in patients with advanced neuroendocrine tumors and small cell lung cancer expressing the somatostatin receptor 2 (SSTR2) is underway, with patients enrolled and treated. The somatostatin receptor is highly expressed in neuroendocrine cancers. PEN-221 is a novel, miniaturized drug conjugate designed to selectively target SSTR2 and then internalize and release its potent DM1 payload in the tumor cell.【閱讀全文】

Mundipharma bags rights to Vectura’s novel respiratory therapy

Mundipharma has signed a deal with Vectura to develop and commercialise VR2076, a novel inhaled triple therapy in development for the treatment of asthma and COPD.【閱讀全文】

TG Therapeutics, Inc. Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the opening of an investigator initiated Phase 2 study at the University of Nebraska Medical Center (UNMC) to evaluate the safety and efficacy of TGR-1202, the Company's oral PI3K delta inhibitor in combination with ibrutinib, in patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL). TG Therapeutics and Janssen Pharmaceuticals will each provide drug and equally share study-related costs.【閱讀全文】

Former Novartis pharmaceuticals chief David Epstein is going biotech

David Epstein is joining a long lineup of execs who are exchanging Big Pharma titles for a prominent place in the biotech world. The former Novartis pharmaceuticals chief is joining the biotech VC Flagship Pioneering as an executive partner, a new role at the trendsetting venture group.【閱讀全文】

Former Novartis exec David Epstein becomes Flagship VC partner

After raising a $285 million special op fund last month, and changing its name from Flagship Ventures to Flagship Pioneering, the VC has also now announced it has taken on Novartis vet David Epstein as its new executive partner as it also brings a new biotech out of its stealth mode.【閱讀全文】

Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN003, a Novel and Highly Selective B-RAF/PI3 Kinase Inhibitor

Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN003, a novel and highly selective B-RAF/phosphoinositide 3-kinase (PI3K) inhibitor. Activation of these two major signaling pathways has been implicated in abnormal cell growth in various human cancers including melanoma, colorectal, breast and lung.【閱讀全文】

Lycera's double-action immuno-oncology drug starts trials

Lycera has pushed the first of its RORgamma agonist immuno-oncology drugs—partnered with Celgene—into early-stage clinical testing.?Current immuno-oncology drugs are often described as "removing the brake" on a cancer patient's immune system, re-arming the body's own defenses against tumors. But Lycera claims its drugs go one step further, applying the accelerator to the immune system to rev up that response.【閱讀全文】

美中藥源原創(chuàng)文章，轉(zhuǎn)載注明出處并添加超鏈接，商業(yè)用途需經(jīng)書面授權(quán)。
★更多深度解析訪問《美中藥源》~

★ 請關(guān)注《美中藥源》微信公眾號 ★